Morning announcement: The clinical research results of BeiDa Pharmaceutical's use of Enzalutamide in adjuvant therapy after surgery have been published in the New England Journal of Medicine.

1) Pathfinder: Applying for the issuance of stocks to a specific entity and obtaining approval from the Shenzhen Stock Exchange Listing Review Center. 2) Jinpu Landscaping: Applying for the issuance of stocks to a specific entity and obtaining approval from the Shenzhen Stock Exchange Listing Review Center. 3) Beta Pharmaceuticals: The study on the postoperative adjuvant treatment of EGFR-positive non-small cell lung cancer in patients with stage IIIB transformed lymphoma with Ensanitinib hydrochloride capsules has been published online in the New England Journal of Medicine.